RANI

Rani Therapeutics Holdings, Inc. [RANI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RANI Stock Summary

Top 10 Correlated ETFs

RANI

Top 10 Correlated Stocks

RANI

In the News

RANI Financial details

Company Rating
-
Market Cap
270.85M
Income
-33.97M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
140
Optionable
No
Shortable
Yes
Earnings
20 Mar 2024
P/E
-1.81
Forward P/E
-
PEG
0.36
P/S
-
P/B
4.57
P/C
-
P/FCF
-4.65
Quick Ratio
8.24
Current Ratio
8.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.33
EPS next Y
-
EPS next Q
-
EPS this Y
-50%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.3%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-25%
-
-
-
-
SMA20
-50%
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-63%
ROE
-162%
ROC
-1.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.82-5.79
52W High
-75.2%
52W Low
+24%
RSI
35
Rel Volume
2.47
Avg Volume
82.44K
Volume
203.24K
Perf Week
-13.89%
Perf Month
-28.32%
Perf Quarter
-47.23%
Perf Half Y
-42.59%
-
-
-
-
Beta
0.916
-
-
Volatility
0.06%, 0.1%
Prev Close
-1.59%
Price
1.24
Change
-8.82%

Something similar

Top by Market Cap
MSFT
VFINX
ABEC.DE
V
LLY.DE
Top Correlated ETFs
BBC
SBIO
BLKC
SOCL
PRNT
Top Correlated Stocks
NVTS
CRSP
LR.PA
VERV
BAY.L
Similar Market Cap
NODK
2B77.DE
MVST
IBMK
VCIP.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 82.44K
  • Market Capitalization 270.85M
  • Employee 140
  • CEO Mr. Talat Imran
  • Headquarters San Jose,CA,US
  • IPO Date 2021-07-30
  • Website https://www.ranitherapeutics.com

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.